Results 51 to 60 of about 106,775 (245)

Intestinal gene expression in pigs: effects of reduced feed intake during weaning and potential impact of dietary components [PDF]

open access: yes, 2011
The weaning transition is characterised by morphological, histological and microbial changes, often leading to weaning-associated disorders. These intestinal changes can partly be ascribed to the lack of luminal nutrition arising from the reduced feed ...
Bauer, E.   +3 more
core   +1 more source

Neuroprotective effects of lixisenatide against propagation of α-synuclein pathology in Parkinson’s disease

open access: yesNeural Regeneration Research
Glucagon-like peptide-1 receptor agonists, originally developed for the treatment of type 2 diabetes mellitus, have been suggested as a potential disease-modifying treatment for Parkinson’s disease.
Shangqi Sun   +10 more
doaj   +1 more source

Nephroprotective potential of glucagon-like peptide-1 receptor agonists

open access: yesСахарный диабет, 2020
Patients with diabetes mellitus (DM), which is a key factor in the development of kidney diseases, are increasingly competing for limited healthcare resources.
Minara S. Shamkhalova   +2 more
doaj   +1 more source

Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells [PDF]

open access: yesEndocrinology and Metabolism, 2014
BackgroundGlucagon-like peptide 1 (GLP-1), an incretin hormone well known for its glucose-lowering effect, was recently reported to exert an anabolic effect on bone. Although the exact mechanism is not known, it likely involves the GLP-1 receptor (GLP-1R)
Yun Kyung Jeon   +10 more
doaj   +1 more source

Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy. [PDF]

open access: yes, 2018
Class B peptide hormone GPCRs are targets for the treatment of major chronic disease. Peptide ligands of these receptors display biased agonism and this may provide future therapeutic advantage.
Andreassen   +70 more
core   +1 more source

Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. [PDF]

open access: yes, 2020
As perspectives on cannabis continue to shift, understanding the physiological and behavioral effects of cannabis use is of paramount importance. Previous data suggest that cannabis use influences food intake, appetite, and metabolism, yet human research
Abulseoud, Osama A   +6 more
core   +1 more source

Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation. [PDF]

open access: yes, 2019
The decrease in incretin effects is an important etiologic component of type 2 diabetes with unknown mechanisms. In an attempt to understand obesity-induced changes in liver oxygen homeostasis, we found that liver HIF-1α expression was increased mainly ...
Bandyopadhyay, Guatam K   +3 more
core  

Cyclic AMP signalling in pancreatic islets [PDF]

open access: yes, 2010
Cyclic 3'5'AMP (cAMP) is an important physiological amplifier of glucose-induced insulin secretion by the pancreatic islet β-cell, where it is formed by the activity of adenylyl cyclases, which are stimulated by glucose, through elevation in ...
Furman, Brian   +2 more
core   +1 more source

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. [PDF]

open access: yes, 2012
Pancreatic duct glands (PDGs) have been hypothesized to give rise to pancreatic intraepithelial neoplasia (PanIN). Treatment with the glucagon-like peptide (GLP)-1 analog, exendin-4, for 12 weeks induced the expansion of PDGs with mucinous metaplasia and
Butler, Peter C   +5 more
core   +1 more source

Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure. [PDF]

open access: yes, 2019
Mice were treated with a fully human monoclonal glucagon receptor antagonistic antibody REMD2.59 following myocardial infarction or pressure overload.
Baal, Ulysis   +8 more
core  

Home - About - Disclaimer - Privacy